A Multidisciplinary Approach to the Management of New and Emerging Therapies for Moderate-to-Severe Atopic Dermatitis

/ Print /
| ShareMore
/ Text Size +
5/20/21 7:30 pm EST
Virtual Webinar
United States

This event is  provided by National Jewish Health.

This educational activity is supported by an independent educational grant from Sanofi Genzyme and Regeneron Pharmaceuticals.

Webinar Overview:

Atopic Dermatitis (AD) is a chronic and complex inflammatory skin condition affecting approximately 13% of children and 7% of adults in the US. The number of therapeutic agents for moderate-to-severe atopic dermatitis is growing rapidly. An increased understanding of current and emerging treatments as well as multidisciplinary strategies for coordination of care is critical for allergists and dermatologists to optimize patient care in moderate-to-severe AD.

This engaging activity, led by allergy and dermatology experts who specialize in AD, will provide multidisciplinary real-world insights into considerations for diagnosis, treatment selection, and longitudinal management based on current and emerging therapies. 

Upon completion of this activity, learners should be better able to:

  • Evaluate current and emerging treatment options for patients with moderate-to-severe AD.
  • Incorporate appropriate considerations, including co-morbidities and safety profiles, into treatment selection of moderate-to-severe AD.
  • Develop multi-disciplinary strategies to select optimal treatment and improve continuity of care for patients with AD.

Target Audience

Dermatologists and allergists, along with physician assistants and nurse practitioners who are involved in the care and treatment of patients with moderate-to-severe atopic dermatitis.

Date and Time:

This webinar will be held on:

  • Thursday, May 20, 2021 7:30 - 8:30 PM EDT
  • Thursday, May 27, 2021 7:30 - 8:30 PM EDT


Donald Y M Leung, MD, PhD (Program Chair)
Edelstein Chair of Pediatric Allergy-Immunology Professor
Head, Division of Pediatric Allergy and Immunology
Department of Pediatrics
National Jewish Health
Denver, CO

Cory A. Dunnick, MD
Director, Clinical Trials
Department of Dermatology
University of Colorado
Aurora, CO

Kanao Otsu, MD, MPH
Assistant Professor
Division of Allergy and Clinical Immunology
Department of Medicine
National Jewish Health
Denver, CO

Elizabeth Swanson, MD
Board Certified Dermatologist
Board Certified Pediatric Dermatologist
Ada West Dermatology
St. Luke’s Children’s Hospital
Boise, ID


  • Physicians – maximum of 1.0 AMA PRA Category 1 Credit
  • All other health care professionals completing this course will be issued a statement of participation.

Accreditation Statement

Physicians: National Jewish Health is accredited by the Accreditation Council for Continuing Medical Education (ACCME) to provide continuing medical education for physicians. 

Credit Designation

  • Physician Credit Designation Statement
    National Jewish Health designates this live activity for a maximum of 1.0 AMA Category 1 Credit™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.

Disclosure of Conflicts of Interest

In accordance with the Accreditation Council for Continuing Medical Education (ACCME), National Jewish Health requires that all program faculty, content developers, reviewers, and others in a position to control the content of this activity disclose to learners the presence or absence of any relevant financial relationships with an ACCME-defined ineligible company. The ACCME defines an “ineligible company” as one whose primary business is producing, marketing, selling, re-selling, or distributing healthcare products used by or on patients. Our goal is to ensure that there is no compromise in the ethical relationship that exists between those in a position to control the content of the activity and those participating in the activity and their respective professional duties. All accredited education activities offered by National Jewish Health are reviewed to ensure a balanced and evidence-based presentation.

All relevant financial relationships among individuals in a position to control the content of this activity have been identified and mitigated according to the Standards of Integrity and Independence in Accredited Education.


Donald Y M Leung, MD, PhD 

  • Advisory Board:  AbbVie, Evommune, Leo Pharma
  • Institutional Grant: Sanofi Regeneron

Elizabeth Swanson, MD 

  • Speaker:  Sanofi Regeneron, Lilly, Janssen, Almirall, Ortho Dermatologics, Pfizer, Amgen
  • Advisory Board:  Sanofi Regeneron, Lilly, Janssen, Ortho Dermatologics

Cory A. Dunnick, MD has no relevant financial relationships to report.

Kanao Otsu, MD, MPH has no relevant financial relationships to report.

Planners and Reviewers

Harold S. Nelson, MD

  • Consultant:  ALK
  • Data Safety Monitoring Board Member: AstraZeneca

Meghan Brenner, MA; Marye Caslavka, MAEd; Andrea Harshman, MHA, CHCP, CMP-HC; Lauren Rieck; and Amen Sergew, MD have no relevant financial relationships to report.

Disclosure of Unlabeled Use

National Jewish Health requires that faculty participating in any CME activity disclose to the audience when discussing any unlabeled or investigational use of any commercial product or device not yet approved for use in the United States.


National Jewish Health ("NJH") and its officers, Board of Directors, faculty, employees, representatives, and other agents (collectively, "NJH Parties") shall not be responsible in any capacity for, and do not warrant any content whatsoever, in any NJH publication or other product (in any medium), or the use or reliance on any such content, and expressly disclaim any and all liability for such content. All such responsibility for content and use of product solely rests with the authors or the advertisers, as the case may be.

By way of example, without limiting the foregoing, this disclaimer of liability applies to the accuracy, completeness, effectiveness, quality, appearance, ideas, or products, as the case may be, of or resulting from, any statements, references, articles, positions, claimed diagnosis, claimed possible treatments, services, or advertising, express or implied, contained in any NJH live meeting, publication, online course or other product.

Furthermore, the content should not be considered medical advice and is not intended to replace consultation with a qualified medical professional. Under no circumstances, including negligence, shall any of the NJH Parties be liable for any DIRECT, INDIRECT, INCIDENTAL, SPECIAL or CONSEQUENTIAL DAMAGES, or LOST PROFITS that result from any of the foregoing, regardless of legal theory and whether or not claimant was advised of the possibility of such damages.

This activity is designed for educational purposes. Participants have a responsibility to utilize this information to enhance their professional development to improve patient outcomes. Conclusions drawn by the participants should be derived from careful consideration of all available scientific information. The participant should use his/her clinical judgment, knowledge, experience, and diagnostic decision-making before applying any information, whether provided here or by others, for any professional use.

Contact Information

For CME questions, please contact: National Jewish Health at:

Contact this CME provider, National Jewish Health, for privacy policy statement information at: